Claire Morando
Aix-Marseille University
4 Papers
16 Citations
Claire Morando is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Pemetrexed & Bevacizumab. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
Fabrice Barlesi,Arnaud Scherpereel,Vera Gorbunova,Radj Gervais,Anders Vikström,Christos Chouaid,Antonio Chella,Jeong-Ho Kim,Myung-Ju Ahn,Martin Reck,Antonio Pazzola,H. T. Kim,Joachim G.J.V. Aerts,Claire Morando,Anderson Loundou,H. Groen,Achim Rittmeyer +16 more
TL;DR: In an unselected population of nsNSCLC patients achieving disease control on platinum-based induction therapy, maintenance with bevacizumab-pemetrexed was associated with a nonsignificant increase in OS over bevacsumab alone.
172
Can we consider immediate complications after thyroidectomy as a quality metric of operation
Jean-Christophe Lifante,Jean-Christophe Lifante,Cécile Payet,Fabrice Menegaux,Frederic Sebag,Jean-Louis Kraimps,Jean-Louis Peix,François Pattou,Cyrille Colin,Antoine Duclos,Laurent Arnalsteen,Robert Caizzo,Bruno Carnaille,Guelareh Dezfoulian,Carole Eberle,Ziad El Khatib,Emmanuel Fernandez,Antoine Lamblin,Marie-France Six,Stéphanie Bourdy,Laetitia Bouveret,Benoît Guibert,Marie-Annick Le Pogam,Gaétan Singier,Pietro Soardo,Sandrine Touzet,Nicolas Voirin,Pascal Auquier,Jean-François Henry,Claire Morando,Sam Van Slycke,Inès Akrout,Fares Benmiloud,Jean-Paul Chigot,Isabelle Colombet,Gaelle Godiris-Petit,Pierre Leyre,Séverine Noullet,B. Royer,Christophe Trésallet,Thibault Desurmont,Claudia Dominguez,Chiara Odasso,Laetitia Rouleau,Yves-Louis Chapuis,Pierre Durieux,Alain Lepape,Frédéric Triponez +47 more
TL;DR: The immediate hypoparathyroidism rate should not be used to assess the quality of thyroidectomy or to monitor the performance of surgeons, because it does not reflect the permanent hypoporathyroidistan rate.
32
Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial.
Achim Rittmeyer,Arnaud Scherpereel,Vera Gorbunova,Radj Gervais,Anders Vikström,Christos Chouaid,Antonio Chella,Joo Hang Kim,Myung-Ju Ahn,Martin Reck,Antonio Pazzola,Heung Tae Kim,Joachim G.J.V. Aerts,Harry J.M. Groen,Claire Morando,Anderson Loundou,Fabrice Barlesi +16 more
TL;DR: AVAPERL was designed to evaluate the safety and efficacy of bevacizumab with or without pemetrexed as continuation maintenance treatment and demonstrated improved progression-free survival (PFS) and met the primary end point.
17
Impact of caring for patients with severe and complex disabilities on health care workers’ quality of life: determinants and specificities
M.C. Rousseau,Karine Baumstarck,Tanguy Leroy,Cherazad Khaldi-Cherif,C. Brisse,Laurent Boyer,Noémie Resseguier,Claire Morando,Thierry Billette de Villemeur,Pascal Auquier +9 more
TL;DR: The aim of this study was to identify the determinants of quality of life of 238 health care workers caring for individuals with severe and complex disabilities.